Skip to main content
Year archive

NOXOPHARM LIMITED — 2019 filings

All 106 regulatory filings released by NOXOPHARM LIMITED (NOX) in 2019, sourced directly from the official regulator.

106 Filings
2019 Period
2019 filings (106)
Filing Released Lang
Ceasing to be a substantial holder 8 pages 368.8KB
Regulatory Filings
2019-12-26 English
Appendix 3B 12 pages 397.6KB
Regulatory Filings
2019-12-22 English
Section 708 Certificate 2 pages 195.9KB
Regulatory Filings
2019-12-22 English
Change of Director's Interest Notice - GK 4 pages 154.2KB
Regulatory Filings
2019-12-22 English
DARRT-1 Clinical Data Webinar 2 pages 246.3KB
Regulatory Filings
2019-12-19 English
Nyrada IPO Offer Fully Subscribed 2 pages 174.1KB
Regulatory Filings
2019-12-16 English
Unlisted Options Expiring 18 January 2020 2 pages 225.9KB
Regulatory Filings
2019-12-12 English
Lodgement of Nyrada Inc Supplementary Prospectus 4 pages 232.9KB
Regulatory Filings
2019-12-08 English
Nyrada Inc Initial Public Offering Opens 2 pages 224.1KB
Regulatory Filings
2019-12-03 English
Appendix 3B 14 pages 398.6KB
Regulatory Filings
2019-12-02 English
Section 708 Certificate 2 pages 160.5KB
Regulatory Filings
2019-12-02 English
AU$2.4m Increase to Funding Agreement 3 pages 200.6KB
Regulatory Filings
2019-12-02 English
Appendix 3B 12 pages 398.2KB
Regulatory Filings
2019-12-02 English
Section 708 Certificate 2 pages 179.8KB
Regulatory Filings
2019-12-02 English
Section 708 Certificate - Notes 9 pages 276.1KB
Regulatory Filings
2019-12-02 English
Positive DARRT-1 Data in Late-Stage Prostate Cancer 4 pages 189.8KB
Regulatory Filings
2019-12-01 English
Trading Halt 2 pages 311.1KB
Regulatory Filings
2019-11-27 English
Lodgement of Nyrada Inc Prospectus - Initial Public Offering 138 pages 4.9MB
Regulatory Filings
2019-11-25 English
Noxopharm 2019 AGM Corporate Presentations 54 pages 16.0MB
Regulatory Filings
2019-11-19 English
Results of Meeting 3 pages 245.8KB
Regulatory Filings
2019-11-19 English
Updated Share Trading Policy 6 pages 234.1KB
Regulatory Filings
2019-11-19 English
Constitution 42 pages 480.6KB
Regulatory Filings
2019-11-19 English
LuPIN Data Being Presented To Conference 3 pages 317.9KB
Regulatory Filings
2019-11-11 English
DARRT-1 Interim Data Presented To Conference 4 pages 888.5KB
Regulatory Filings
2019-11-11 English
Appointment of Chief Commercial Officer 2 pages 257.8KB
Regulatory Filings
2019-11-05 English
Appendix 4C - Quarterly 10 pages 340.3KB
Regulatory Filings
2019-10-29 English
Noxopharm October 2019 Newsletter 11 pages 2.5MB
Regulatory Filings
2019-10-29 English
Dr Graham Kelly to Assume CEO Role 2 pages 153.6KB
Regulatory Filings
2019-10-27 English
Section 708 Certificate 2 pages 158.0KB
Regulatory Filings
2019-10-24 English
Appendix 3B 12 pages 449.1KB
Regulatory Filings
2019-10-24 English
NOX and Nyrada TechKnow Invest Roadshow Presentations 42 pages 5.4MB
Regulatory Filings
2019-10-21 English
Durable Anti-Cancer Effect Confirmed in DARRT-1 Study 3 pages 184.9KB
Regulatory Filings
2019-10-20 English
Potential Fundamental Change in Treatment of Brain Cancer 3 pages 156.0KB
Regulatory Filings
2019-10-17 English
Notice of 2019 Annual General Meeting & Proxy Form 28 pages 489.8KB
Regulatory Filings
2019-10-17 English
Final Director's Interest Notice 2 pages 193.6KB
Regulatory Filings
2019-10-15 English
New Executive Appointments and Board Change 4 pages 192.0KB
Regulatory Filings
2019-10-15 English
FNN Interview with Graham on recent LuPIN interim data 2 pages 133.1KB
Regulatory Filings
2019-10-01 English
Noxopharm 2019 Annual General Meeting Details 2 pages 139.0KB
Regulatory Filings
2019-10-01 English
Further Review Shows Major Clinical Benefits from Veyonda 4 pages 184.1KB
Regulatory Filings
2019-09-29 English
Appendix 3B 12 pages 454.8KB
Regulatory Filings
2019-09-25 English
Section 708 Certificate 11 pages 312.8KB
Regulatory Filings
2019-09-25 English
Section 708 Certificate 2 pages 153.3KB
Regulatory Filings
2019-09-25 English
Corporate Governance Statement 8 pages 301.9KB
Regulatory Filings
2019-09-25 English
Appendix 4G 12 pages 221.5KB
Regulatory Filings
2019-09-25 English
Annual Report to Shareholders 66 pages 2.3MB
Regulatory Filings
2019-09-25 English
Departure of Dr Wan Wyk 2 pages 147.1KB
Regulatory Filings
2019-09-23 English
Amended/Departure of Dr Van Wyk 2 pages 147.2KB
Regulatory Filings
2019-09-23 English
Veyonda and Radiotherapy Profiled at Key Oncology Meeting 4 pages 203.2KB
Regulatory Filings
2019-09-16 English
NOX EGM Chairman's Address and Presentation 29 pages 739.0KB
Regulatory Filings
2019-09-15 English
Results of Meeting 3 pages 194.9KB
Regulatory Filings
2019-09-15 English
CHANGE OF DIRECTOR'S INTEREST NOTICE - GK 4 pages 218.0KB
Regulatory Filings
2019-09-11 English
CHANGE OF DIRECTOR'S INTEREST NOTICE - GK 4 pages 218.1KB
Regulatory Filings
2019-09-09 English
Appendix 4E and Audited Financial Statements FY19 53 pages 1.8MB
Regulatory Filings
2019-08-28 English
More Evidence that Veyonda Enhances RT in Prostate Cancer 6 pages 222.1KB
Regulatory Filings
2019-08-27 English
Addendum to Notice of Extraordinary General Meeting 5 pages 205.8KB
Regulatory Filings
2019-08-27 English
Cleansing Statement 2 pages 160.1KB
Regulatory Filings
2019-08-22 English
Appendix 3B 12 pages 388.3KB
Regulatory Filings
2019-08-22 English
NOX Receives FY19 Federal Government R&D Tax Rebate 2 pages 155.6KB
Regulatory Filings
2019-08-22 English
Pre-Clinical Evidence Confirms Veyonda Abscopal Effect 3 pages 221.7KB
Regulatory Filings
2019-08-20 English
Lead Manager Appointed for Proposed Nyrada IPO 2 pages 266.5KB
Regulatory Filings
2019-08-14 English
Notice of Extraordinary General Meeting/Proxy Form 27 pages 655.3KB
Regulatory Filings
2019-08-11 English
Noxopharm Corporate Update Interview 2 pages 223.8KB
Regulatory Filings
2019-08-08 English
Noxopharm August 2019 Corporate Presentation 41 pages 19.5MB
Regulatory Filings
2019-08-06 English
NOX Releases Initial Newsletter for Nyrada Subsidiary 10 pages 3.2MB
Regulatory Filings
2019-08-01 English
Appendix 4C - Quarterly 12 pages 425.3KB
Regulatory Filings
2019-07-28 English
Section 708 Certificate 7 pages 295.0KB
Regulatory Filings
2019-07-24 English
Appendix 3B 12 pages 394.5KB
Regulatory Filings
2019-07-24 English
Section 708 Certificate 1 page 142.7KB
Regulatory Filings
2019-07-22 English
Appendix 3B 12 pages 394.1KB
Regulatory Filings
2019-07-22 English
NOX Announces AU$26 Million Funding Facility 4 pages 290.6KB
Regulatory Filings
2019-07-18 English
Final Director's Interest Notice 2 pages 195.7KB
Regulatory Filings
2019-07-18 English
Initial Director's Interest Notice 2 pages 130.2KB
Regulatory Filings
2019-07-18 English
NOX Releases Latest Newsletter 12 pages 2.8MB
Regulatory Filings
2019-07-16 English
Board Changes Ahead of Corporate Growth 4 pages 344.5KB
Regulatory Filings
2019-07-15 English
SNMMI 2019 Conference LuPIN Presentation Released 2 pages 304.8KB
Regulatory Filings
2019-07-01 English
Conference Hears of Positive Interim Data from LuPIN Trial 4 pages 369.6KB
Regulatory Filings
2019-06-25 English
NOX Subsidiary, Nyrada Inc, Receives R&D Rebate 2 pages 167.0KB
Regulatory Filings
2019-06-06 English
Noxopharm Corporate Presentation June 2019 25 pages 7.4MB
Regulatory Filings
2019-06-05 English
DARRT-1 Study Fully Enrolled 3 pages 167.5KB
Regulatory Filings
2019-05-29 English
Promising Data Leads to Expansion of LuPIN Trial 3 pages 169.4KB
Regulatory Filings
2019-05-22 English
LuPIN Trial Demonstrates High Rates of Response 4 pages 207.1KB
Regulatory Filings
2019-05-19 English
Appendix 3B 12 pages 387.9KB
Regulatory Filings
2019-05-07 English
Change of Director's Interest Notice - GK 4 pages 152.1KB
Regulatory Filings
2019-05-07 English
DARRT Treatment Has Lasting Disease Control at Six Months 4 pages 199.9KB
Regulatory Filings
2019-05-01 English
Veyonda and Immuno-Oncology Effect Explained 3 pages 201.5KB
Regulatory Filings
2019-04-28 English
Appendix 4C - Quarterly 9 pages 433.3KB
Regulatory Filings
2019-04-25 English
Change in Noxopharm Limited Board Structure 2 pages 186.2KB
Regulatory Filings
2019-04-22 English
Idronoxil Confirmed as New Immuno-Oncology Drug 2 pages 212.7KB
Regulatory Filings
2019-04-15 English
Veyonda Chemotherapy Enhancement Program to be Expanded 3 pages 274.8KB
Regulatory Filings
2019-04-09 English
Securities to be released from Voluntary Escrow 1 p
Regulatory Filings
2019-04-07 English
Updated Top 20 shareholder List 3 pages 178.3KB
Regulatory Filings
2019-04-04 English
Section 708 Certificate 1 page 142.3KB
Regulatory Filings
2019-03-24 English
Appendix 3B 11 pages 399.9KB
Regulatory Filings
2019-03-24 English
Becoming a substantial holder 4 pages 141.4KB
Regulatory Filings
2019-03-20 English
KZA: Kazia sells stake in Noxopharm 1 page 148.7KB
Regulatory Filings
2019-03-18 English
NOX provides update to Nyrada Note Holders 7 pages 332.1KB
Regulatory Filings
2019-03-05 English
New Corporate Presentation Released 25 pages 13.4MB
Regulatory Filings
2019-03-04 English
Appendix 4D and Half Year Accounts 19 pages 412.9KB
Regulatory Filings
2019-02-20 English
Noxopharm to expedite Veyonda Clinical Program 4 pages 174.8KB
Regulatory Filings
2019-02-20 English
Change of Director's Interest Notice - GK 4 pages 216.3KB
Regulatory Filings
2019-02-13 English
Updated Share Trading Policy 6 pages 227.5KB
Regulatory Filings
2019-02-07 English
Veyonda and Radiotherapy Delivers Clinical Benefits 5 pages 741.4KB
Regulatory Filings
2019-02-05 English
FNN interview with Nox Chief Medical Officer on Interim Data 2 pages 157.8KB
Regulatory Filings
2019-02-05 English
Appendix 3B 11 pages 400.8KB
Regulatory Filings
2019-01-31 English
Appendix 4C - Quarterly 10 pages 461.3KB
Regulatory Filings
2019-01-28 English
Principal Investigator Discusses LuPIN-1 Study 3 pages 168.2KB
Regulatory Filings
2019-01-13 English